A newly isolated E. thailandicus strain d5B with exclusively antimicrobial activity against C. difficile might be a novel therapy for controlling CDI.
Genomics
; 113(1 Pt 2): 475-483, 2021 01.
Article
en En
| MEDLINE
| ID: mdl-32956846
Colitis induced by C. difficile is one of the most common and costly healthcare-related infections for humans. Probiotics are one of the most promising approaches for controlling CDI. Here, we presented the isolation, safety, and probiotic property evaluation of a novel E. thailandicus strain, d5B, with effective antimicrobial activity against C. difficile. Strain d5B showed strong bactericidal effects on at least 54C. difficile strains. Safety tests showed that strain d5B was sensitive to clinically important antibiotics, and had no haemolytic and cytotoxic activities. Whole genomic analysis showed strain d5B only contained one aminoglycoside resistance gene located in the chromosome. Moreover, d5B was devoid of functional virulence genes. Finally, strain d5B exhibited probiotic properties, such as tolerance to the gastrointestinal tract, and adhered well to HT-29 cells. In conclusion, the E. thailandicus strain d5B should be investigated further for useful properties as a novel candidate probiotic for controlling CDI.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Clostridioides difficile
/
Enterococcus
/
Antibacterianos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Genomics
Asunto de la revista:
GENETICA
Año:
2021
Tipo del documento:
Article
País de afiliación:
China